Notably, HGF/c-MET inhibition has been shown in preclinical models to increase drug delivery and improve chemotherapeutic response both in genetically engineered mouse models [85] and orthotopic models of pancreatic cancer [53,86]. The gene discussed is MET; the disease is pancreatic neoplasm.